Merus Reveals FDA Approval and Expedited Assessment of BLA for Zeno to Manage NRG1+ Lung and Pancreatic Cancer.

Canagliflozin, marketed under the brand name Invokana, is a medication developed by Janssen Pharmaceuticals, a division of Johnson & Johnson, for the treatment of type 2 diabetes mellitus.

Positive Phase 2 Results for XyloCor Therapeutics’ Main Candidate XC001 Announced at SCAI 2024 and in the Journal Circulation: Cardiovascular Interventions.

At the upcoming ASCO conference, Mabwell (Shanghai) Bioscience will present the Phase I/II clinical study results of 9MW2821 for several advanced solid tumors through an oral report.

Age-standardized rate refers to a statistical measure that allows for the comparison of health-related rates, such as disease incidence or mortality rates, between populations with different age structures.

May 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Blinatumomab, sold under the brand name Blincyto, is a breakthrough cancer treatment developed by Amgen Inc.

Context Therapeutics has received FDA approval for its IND application, initiating a Phase 1 clinical trial of CTIM-76.

Loncastuximab tesirine, marketed under the brand name Zynlonta, is a targeted antibody-drug conjugate (ADC) developed by ADC Therapeutics SA.

Remix Therapeutics has started dosing the first participants in a pair of Phase 1 studies. These trials are testing REM-422 in treating Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS).

JSKN003 is a novel ADC targeting two distinct epitopes of HER2, independently developed by Alphamab Biopharmaceuticals utilizing its proprietary glycan-based site-specific conjugation platform.

Alpha-9 Oncology reports initial dosing of the first participant in a phase 1 trial for A9-3202, targeting locally advanced or metastatic melanoma patients.